Emrosi, minocycline ER 40 mg
Named-patient access overview. Emrosi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Emrosi
Emrosi (minocycline hydrochloride extended-release capsules, 40 mg once daily) is manufactured by Journey Medical Corporation and was approved by the US FDA in 2024 for the treatment of inflammatory lesions of rosacea in adults. The 40 mg daily dose is a low, sub-antimicrobial dose of minocycline; the clinical rationale is anti-inflammatory rather than antibacterial, which is the basis on which the FDA evaluated the MVOR-1 and MVOR-2 Phase 3 trials supporting approval.
Emrosi is taken orally once daily on an empty stomach as set out in the prescribing information, with the usual tetracycline-class precautions including photosensitivity, vestibular effects, and contraindication in pregnancy and in children under eight. For international patients, Emrosi may be coordinated through Named Patient Program or personal-import pathways with the destination country's regulator and the prescribing physician handling the documentation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Emrosi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Emrosi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Emrosi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Emrosi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Emrosi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.